TY - JOUR
T1 - Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
AU - Falletta, Paola
AU - Sanchez-del-Campo, Luis
AU - Chauhan, Jagat
AU - Effern, Maike
AU - Kenyon, Amy
AU - Kershaw, Christopher J.
AU - Siddaway, Robert
AU - Lisle, Richard
AU - Freter, Rasmus
AU - Daniels, Matthew J.
AU - Lu, Xin
AU - Tüting, Thomas
AU - Middleton, Mark
AU - Buffa, Francesca M.
AU - Willis, Anne E.
AU - Pavitt, Graham
AU - Ronai, Ze’Ev A.
AU - Sauka-Spengler, Tatjana
AU - Hölzel, Michael
AU - Goding, Colin R.
N1 - Publisher Copyright:
© 2017 Falletta et al.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The intratumor microenvironment generates phenotypically distinct but interconvertible malignant cell subpopulations that fuel metastatic spread and therapeutic resistance. Whether different microenvironmental cues impose invasive or therapy-resistant phenotypes via a common mechanism is unknown. In melanoma, low expression of the lineage survival oncogene microphthalmia-associated transcription factor (MITF) correlates with invasion, senescence, and drug resistance. However, how MITF is suppressed in vivo and how MITF-low cells in tumors escape senescence are poorly understood. Here we show that microenvironmental cues, including inflammationmediated resistance to adoptive T-cell immunotherapy, transcriptionally repress MITF via ATF4 in response to inhibition of translation initiation factor eIF2B. ATF4, a key transcription mediator of the integrated stress response, also activates AXL and suppresses senescence to impose the MITF-low/AXL-high drug-resistant phenotype observed in human tumors. However, unexpectedly, without translation reprogramming an ATF4-high/MITF-low state is insufficient to drive invasion. Importantly, translation reprogramming dramatically enhances tumorigenesis and is linked to a previously unexplained gene expression program associated with anti-PD-1 immunotherapy resistance. Since we show that inhibition of eIF2B also drives neural crest migration and yeast invasiveness, our results suggest that translation reprogramming, an evolutionarily conserved starvation response, has been hijacked by microenvironmental stress signals in melanoma to drive phenotypic plasticity and invasion and determine therapeutic outcome.
AB - The intratumor microenvironment generates phenotypically distinct but interconvertible malignant cell subpopulations that fuel metastatic spread and therapeutic resistance. Whether different microenvironmental cues impose invasive or therapy-resistant phenotypes via a common mechanism is unknown. In melanoma, low expression of the lineage survival oncogene microphthalmia-associated transcription factor (MITF) correlates with invasion, senescence, and drug resistance. However, how MITF is suppressed in vivo and how MITF-low cells in tumors escape senescence are poorly understood. Here we show that microenvironmental cues, including inflammationmediated resistance to adoptive T-cell immunotherapy, transcriptionally repress MITF via ATF4 in response to inhibition of translation initiation factor eIF2B. ATF4, a key transcription mediator of the integrated stress response, also activates AXL and suppresses senescence to impose the MITF-low/AXL-high drug-resistant phenotype observed in human tumors. However, unexpectedly, without translation reprogramming an ATF4-high/MITF-low state is insufficient to drive invasion. Importantly, translation reprogramming dramatically enhances tumorigenesis and is linked to a previously unexplained gene expression program associated with anti-PD-1 immunotherapy resistance. Since we show that inhibition of eIF2B also drives neural crest migration and yeast invasiveness, our results suggest that translation reprogramming, an evolutionarily conserved starvation response, has been hijacked by microenvironmental stress signals in melanoma to drive phenotypic plasticity and invasion and determine therapeutic outcome.
KW - Invasiveness
KW - MITF
KW - Melanoma
KW - Phenotype-switching
KW - TNFα
UR - http://www.scopus.com/inward/record.url?scp=85011615040&partnerID=8YFLogxK
U2 - 10.1101/gad.290940.116
DO - 10.1101/gad.290940.116
M3 - Article
C2 - 28096186
AN - SCOPUS:85011615040
SN - 0890-9369
VL - 31
SP - 18
EP - 33
JO - Genes and Development
JF - Genes and Development
IS - 1
ER -